Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
- Fourth-quarter GAAP diluted EPS of
$1.01 ; adjusted diluted EPS of$1.50 reflects growth of 12 percent - Full-year 2025 GAAP diluted EPS of
$3.72 ; adjusted diluted EPS of$5.15 reflects growth of 10 percent Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of$5.55 to$5.80 , which reflects 10 percent growth at the midpoint
- Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-related sales1.
- Fourth-quarter GAAP diluted EPS of
$1.01 and adjusted diluted EPS of$1.50 , which excludes specified items and reflects growth of 12 percent. - Full-year 2025 sales of
$44.3 billion increased 5.7 percent on a reported basis, 5.5 percent on an organic basis, or 6.7 percent when excluding COVID-19 testing-related sales2. - Full-year 2025 GAAP diluted EPS of
$3.72 and adjusted diluted EPS of$5.15 , which excludes specified items and reflects growth of 10 percent. Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.Abbott projects full-year 2026 adjusted diluted EPS of$5.55 to$5.80 , which reflects growth of 10 percent at the midpoint.- In November,
Abbott announced an agreement to acquire Exact Sciences, a move that will position the company to enter and lead in the fast-growing cancer diagnostics market.Abbott continues to expect the transaction to close in the second quarter of 2026. Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals:- In December,
Abbott announcedU.S. Food and Drug Administration (FDA) approval for its Volt™ PFA System, bringingAbbott 's first pulsed field ablation (PFA) offering to patients inthe United States . - In January,
Abbott announced the company obtained CE Mark for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver radiofrequency (RF) and PFA energy to treat patients battling atrial fibrillation.
- In December,
"In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future," said
FOURTH-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.
Note: In order to compute results excluding the impact of exchange rates, current year
|
Fourth Quarter 2025 Results (4Q25) |
|||||||||
|
Sales 4Q25 ($ in millions) |
|
Nutrition |
Diagnostics |
Established |
Medical Devices |
||||
|
|
4,383 |
806 |
967 |
— |
2,605 |
||||
|
International |
7,076 |
1,134 |
1,490 |
1,382 |
3,070 |
||||
|
Total reported |
11,459 |
1,940 |
2,457 |
1,382 |
5,675 |
||||
|
% Change vs. 4Q24 |
|||||||||
|
|
0.9 |
(13.2) |
(8.4) |
n/a |
10.7 |
||||
|
International |
6.7 |
(5.6) |
1.8 |
9.0 |
13.7 |
||||
|
Total reported |
4.4 |
(8.9) |
(2.5) |
9.0 |
12.3 |
||||
|
Impact of foreign exchange |
1.4 |
0.2 |
1.1 |
2.0 |
1.9 |
||||
|
Organic |
3.0 |
(9.1) |
(3.6) |
7.0 |
10.4 |
||||
|
Impact of COVID-19 testing sales 1 |
(0.8) |
— |
(3.4) |
— |
— |
||||
|
Organic (excluding COVID-19 tests) |
3.8 |
(9.1) |
(0.2) |
7.0 |
10.4 |
||||
|
Organic |
|||||||||
|
|
0.9 |
(13.2) |
(8.4) |
n/a |
10.7 |
||||
|
International |
4.3 |
(5.9) |
(0.2) |
7.0 |
10.1 |
||||
|
Full-Year 2025 Results (12M25) |
|||||||||
|
Sales 12M25 ($ in millions) |
|
Nutrition |
Diagnostics |
Established |
Medical Devices |
||||
|
|
17,126 |
3,606 |
3,535 |
— |
9,968 |
||||
|
International |
27,202 |
4,845 |
5,402 |
5,536 |
11,419 |
||||
|
Total reported |
44,328 |
8,451 |
8,937 |
5,536 |
21,387 |
||||
|
% Change vs. 12M24 |
|||||||||
|
|
4.9 |
(2.3) |
(7.7) |
n/a |
13.4 |
||||
|
International |
6.1 |
2.6 |
(2.0) |
6.6 |
12.0 |
||||
|
Total reported |
5.7 |
0.4 |
(4.3) |
6.6 |
12.6 |
||||
|
Impact of foreign exchange |
0.2 |
(0.7) |
0.2 |
(0.8) |
0.7 |
||||
|
Impact of business exit* |
— |
(0.1) |
— |
— |
— |
||||
|
Organic |
5.5 |
1.2 |
(4.5) |
7.4 |
11.9 |
||||
|
Impact of COVID-19 testing sales 2 |
(1.2) |
— |
(4.9) |
— |
— |
||||
|
Organic (excluding COVID-19 tests) |
6.7 |
1.2 |
0.4 |
7.4 |
11.9 |
||||
|
Organic |
|||||||||
|
|
5.0 |
(1.9) |
(7.7) |
n/a |
13.4 |
||||
|
International |
5.9 |
3.7 |
(2.3) |
7.4 |
10.5 |
||||
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.
|
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in |
|
Nutrition |
|||||
|
Fourth Quarter 2025 Results (4Q25) |
|||||
|
Sales 4Q25 ($ in millions) |
Total |
Pediatric |
Adult |
||
|
|
806 |
463 |
343 |
||
|
International |
1,134 |
439 |
695 |
||
|
Total reported |
1,940 |
902 |
1,038 |
||
|
% Change vs. 4Q24 |
|||||
|
|
(13.2) |
(17.7) |
(6.3) |
||
|
International |
(5.6) |
0.3 |
(8.9) |
||
|
Total reported |
(8.9) |
(9.8) |
(8.1) |
||
|
Impact of foreign exchange |
0.2 |
0.3 |
0.1 |
||
|
Organic |
(9.1) |
(10.1) |
(8.2) |
||
|
|
(13.2) |
(17.7) |
(6.3) |
||
|
International |
(5.9) |
(0.3) |
(9.1) |
||
Worldwide Nutrition sales decreased 8.9 percent on a reported basis and 9.1 percent on an organic basis in the fourth quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and new strategic price actions targeted to increase volume growth in the future. In addition to these strategic price actions,
|
Full-Year 2025 Results (12M25) |
|||||
|
Sales 12M25 ($ in millions) |
Total |
Pediatric |
Adult |
||
|
|
3,606 |
2,158 |
1,448 |
||
|
International |
4,845 |
1,816 |
3,029 |
||
|
Total reported |
8,451 |
3,974 |
4,477 |
||
|
% Change vs. 12M24 |
|||||
|
|
(2.3) |
(2.3) |
(2.2) |
||
|
International |
2.6 |
0.1 |
4.1 |
||
|
Total reported |
0.4 |
(1.2) |
2.0 |
||
|
Impact of foreign exchange |
(0.7) |
(0.5) |
(0.7) |
||
|
Impact of business exit* |
(0.1) |
— |
(0.3) |
||
|
Organic |
1.2 |
(0.7) |
3.0 |
||
|
|
(1.9) |
(2.3) |
(1.4) |
||
|
International |
3.7 |
1.3 |
5.1 |
||
|
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in |
|
Diagnostics |
|||||||||
|
Fourth Quarter 2025 Results (4Q25) |
|||||||||
|
Sales 4Q25 ($ in millions) |
Total |
|
Molecular |
Point of |
|
||||
|
|
967 |
376 |
39 |
107 |
445 |
||||
|
International |
1,490 |
1,085 |
102 |
51 |
252 |
||||
|
Total reported |
2,457 |
1,461 |
141 |
158 |
697 |
||||
|
% Change vs. 4Q24 |
|||||||||
|
|
(8.4) |
3.6 |
2.9 |
6.5 |
(19.7) |
||||
|
International |
1.8 |
5.9 |
3.3 |
9.8 |
(14.1) |
||||
|
Total reported |
(2.5) |
5.3 |
3.2 |
7.5 |
(17.8) |
||||
|
Impact of foreign exchange |
1.1 |
1.7 |
2.1 |
0.4 |
0.3 |
||||
|
Organic |
(3.6) |
3.6 |
1.1 |
7.1 |
(18.1) |
||||
|
|
(8.4) |
3.6 |
2.9 |
6.5 |
(19.7) |
||||
|
International |
(0.2) |
3.6 |
0.4 |
8.3 |
(14.9) |
||||
COVID-19 testing-related sales were
|
Full-Year 2025 Results (12M25) |
|||||||||
|
Sales 12M25 ($ in millions) |
Total |
|
Molecular |
Point of |
|
||||
|
|
3,535 |
1,425 |
150 |
422 |
1,538 |
||||
|
International |
5,402 |
3,935 |
367 |
184 |
916 |
||||
|
Total reported |
8,937 |
5,360 |
517 |
606 |
2,454 |
||||
|
% Change vs. 12M24 |
|||||||||
|
|
(7.7) |
7.0 |
0.4 |
3.4 |
(20.8) |
||||
|
International |
(2.0) |
0.8 |
(1.1) |
2.5 |
(13.3) |
||||
|
Total reported |
(4.3) |
2.4 |
(0.7) |
3.1 |
(18.1) |
||||
|
Impact of foreign exchange |
0.2 |
0.3 |
0.5 |
— |
(0.1) |
||||
|
Organic |
(4.5) |
2.1 |
(1.2) |
3.1 |
(18.0) |
||||
|
|
(7.7) |
7.0 |
0.4 |
3.4 |
(20.8) |
||||
|
International |
(2.3) |
0.4 |
(1.8) |
2.4 |
(13.1) |
||||
|
|
|||||
|
Fourth Quarter 2025 Results (4Q25) |
|||||
|
Sales 4Q25 ($ in millions) |
Total |
Key Emerging |
Other |
||
|
|
— |
— |
— |
||
|
International |
1,382 |
1,046 |
336 |
||
|
Total reported |
1,382 |
1,046 |
336 |
||
|
% Change vs. 4Q24 |
|||||
|
|
n/a |
n/a |
n/a |
||
|
International |
9.0 |
10.3 |
5.0 |
||
|
Total reported |
9.0 |
10.3 |
5.0 |
||
|
Impact of foreign exchange |
2.0 |
1.6 |
3.1 |
||
|
Organic |
7.0 |
8.7 |
1.9 |
||
|
|
n/a |
n/a |
n/a |
||
|
International |
7.0 |
8.7 |
1.9 |
||
Key
|
Full-Year 2025 Results (12M25) |
|||||
|
Sales 12M25 ($ in millions) |
Total |
Key Emerging |
Other |
||
|
|
— |
— |
— |
||
|
International |
5,536 |
4,167 |
1,369 |
||
|
Total reported |
5,536 |
4,167 |
1,369 |
||
|
% Change vs. 12M24 |
|||||
|
|
n/a |
n/a |
n/a |
||
|
International |
6.6 |
8.0 |
2.5 |
||
|
Total reported |
6.6 |
8.0 |
2.5 |
||
|
Impact of foreign exchange |
(0.8) |
(1.5) |
1.1 |
||
|
Organic |
7.4 |
9.5 |
1.4 |
||
|
|
n/a |
n/a |
n/a |
||
|
International |
7.4 |
9.5 |
1.4 |
||
|
Medical Devices |
|||||||||||||||
|
Fourth Quarter 2025 Results (4Q25) |
|||||||||||||||
|
Sales 4Q25 ($ in millions) |
Total |
Rhythm |
Electro- physiology |
Heart |
Vascular |
Structural |
Neuro- |
Diabetes |
|||||||
|
|
2,605 |
340 |
340 |
283 |
287 |
304 |
208 |
843 |
|||||||
|
International |
3,070 |
365 |
390 |
92 |
496 |
371 |
66 |
1,290 |
|||||||
|
Total reported |
5,675 |
705 |
730 |
375 |
783 |
675 |
274 |
2,133 |
|||||||
|
% Change vs. 4Q24 |
|||||||||||||||
|
|
10.7 |
12.8 |
13.1 |
11.7 |
6.5 |
4.8 |
1.9 |
14.9 |
|||||||
|
International |
13.7 |
13.4 |
13.9 |
17.9 |
8.9 |
16.3 |
23.8 |
14.2 |
|||||||
|
Total reported |
12.3 |
13.1 |
13.5 |
13.2 |
8.0 |
10.8 |
6.5 |
14.5 |
|||||||
|
Impact of foreign exchange |
1.9 |
1.6 |
1.0 |
1.1 |
1.5 |
2.1 |
0.9 |
2.8 |
|||||||
|
Organic |
10.4 |
11.5 |
12.5 |
12.1 |
6.5 |
8.7 |
5.6 |
11.7 |
|||||||
|
|
10.7 |
12.8 |
13.1 |
11.7 |
6.5 |
4.8 |
1.9 |
14.9 |
|||||||
|
International |
10.1 |
10.2 |
11.9 |
13.4 |
6.6 |
12.3 |
19.6 |
9.6 |
|||||||
Worldwide Medical Devices sales increased 12.3 percent on a reported basis and 10.4 percent on an organic basis in the fourth quarter.
Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management.
In Diabetes Care, sales of continuous glucose monitors were
|
Full-Year 2025 Results (12M25) |
|||||||||||||||
|
Sales 12M25 ($ in millions) |
Total |
Rhythm |
Electro- physiology |
Heart |
Vascular |
Structural |
Neuro- |
Diabetes |
|||||||
|
|
9,968 |
1,334 |
1,283 |
1,107 |
1,118 |
1,172 |
773 |
3,181 |
|||||||
|
International |
11,419 |
1,315 |
1,481 |
341 |
1,877 |
1,351 |
237 |
4,817 |
|||||||
|
Total reported |
21,387 |
2,649 |
2,764 |
1,448 |
2,995 |
2,523 |
1,010 |
7,998 |
|||||||
|
% Change vs. 12M24 |
|||||||||||||||
|
|
13.4 |
15.7 |
12.4 |
12.2 |
5.8 |
11.5 |
0.8 |
20.8 |
|||||||
|
International |
12.0 |
6.4 |
11.7 |
16.4 |
5.4 |
13.0 |
21.5 |
15.4 |
|||||||
|
Total reported |
12.6 |
10.9 |
12.0 |
13.2 |
5.6 |
12.3 |
5.0 |
17.5 |
|||||||
|
Impact of foreign exchange |
0.7 |
0.7 |
0.4 |
0.5 |
0.5 |
0.8 |
0.2 |
1.2 |
|||||||
|
Organic |
11.9 |
10.2 |
11.6 |
12.7 |
5.1 |
11.5 |
4.8 |
16.3 |
|||||||
|
|
13.4 |
15.7 |
12.4 |
12.2 |
5.8 |
11.5 |
0.8 |
20.8 |
|||||||
|
International |
10.5 |
5.0 |
10.9 |
14.3 |
4.7 |
11.5 |
20.5 |
13.5 |
|||||||
On
About
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
|
1. |
In the fourth quarter of 2025, total worldwide sales were |
|
2. |
In the full-year 2025, total worldwide sales were |
|
Condensed Consolidated Statement of Earnings Fourth Quarter Ended (in millions, except per share data) (unaudited) |
||||||
|
4Q25 |
4Q24 |
% Change |
||||
|
|
|
|
4.4 |
|||
|
Cost of products sold, excluding amortization expense |
4,922 |
4,942 |
(0.4) |
|||
|
Amortization of intangible assets |
422 |
465 |
(9.4) |
|||
|
Research and development |
735 |
749 |
(1.9) |
|||
|
Selling, general, and administrative |
3,129 |
2,907 |
7.7 |
|||
|
Total Operating Cost and Expenses |
9,208 |
9,063 |
1.6 |
|||
|
Operating Earnings |
2,251 |
1,911 |
17.8 |
|||
|
Interest expense, net |
42 |
45 |
(8.0) |
|||
|
Net foreign exchange (gain) loss |
(15) |
(10) |
n/m |
|||
|
Other (income) expense, net |
(134) |
(154) |
(13.0) |
|||
|
Earnings before taxes |
2,358 |
2,030 |
16.1 |
|||
|
Taxes on earnings |
582 |
(7,199) |
n/m |
1) |
||
|
Net Earnings |
|
|
n/m |
|||
|
Net Earnings excluding Specified Items, as described below |
|
|
11.9 |
2) |
||
|
Diluted Earnings per Common Share |
|
|
n/m |
|||
|
Diluted Earnings per Common Share, excluding Specified Items, as described below |
|
|
11.9 |
2) |
||
|
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options |
1,747 |
1,746 |
||||
|
NOTES: |
|
|
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. |
|
|
n/m = Percent change is not meaningful. |
|
|
See footnotes on the following section. |
|
|
1) |
2025 Taxes on Earnings includes the recognition of approximately |
|
2024 Taxes on Earnings includes |
|
|
2) |
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of |
|
2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax benefits of |
|
|
Condensed Consolidated Statement of Earnings Twelve Months Ended (in millions, except per share data) (unaudited) |
||||||
|
12M25 |
12M24 |
% Change |
||||
|
|
|
|
5.7 |
|||
|
Cost of products sold, excluding amortization expense |
19,319 |
18,706 |
3.3 |
|||
|
Amortization of intangible assets |
1,682 |
1,878 |
(10.5) |
|||
|
Research and development |
2,942 |
2,844 |
3.5 |
|||
|
Selling, general, and administrative |
12,332 |
11,697 |
5.4 |
|||
|
Total Operating Cost and Expenses |
36,275 |
35,125 |
3.3 |
|||
|
Operating Earnings |
8,053 |
6,825 |
18.0 |
|||
|
Interest expense, net |
185 |
215 |
(13.8) |
|||
|
Net foreign exchange (gain) loss |
(50) |
(27) |
n/m |
|||
|
Other (income) expense, net |
(548) |
(376) |
45.9 |
|||
|
Earnings before taxes |
8,466 |
7,013 |
20.7 |
|||
|
Taxes on earnings |
1,942 |
(6,389) |
n/m |
1) |
||
|
Net Earnings |
|
|
n/m |
|||
|
Net Earnings excluding Specified Items, as described below |
|
|
10.2 |
2) |
||
|
Diluted Earnings per Common Share |
|
|
n/m |
|||
|
Diluted Earnings per Common Share, excluding Specified Items, as described below |
|
|
10.3 |
2) |
||
|
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options |
1,749 |
1,748 |
||||
|
NOTES: |
|
|
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. |
|
|
n/m = Percent change is not meaningful. |
|
|
See footnotes on the following section. |
|
|
1) |
2025 Taxes on Earnings includes the recognition of approximately |
|
2024 Taxes on Earnings includes |
|
|
2) |
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of |
|
2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax benefits of |
|
|
Non-GAAP Reconciliation of Financial Information Fourth Quarter Ended (in millions, except per share data) (unaudited) |
|||||
|
4Q25 |
|||||
|
As |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 422 |
$ (422) |
$ — |
||
|
Gross Margin |
6,115 |
428 |
6,543 |
||
|
R&D |
735 |
(29) |
706 |
||
|
SG&A |
3,129 |
(254) |
2,875 |
||
|
Other (income) expense, net |
(134) |
(17) |
(151) |
||
|
Earnings before taxes |
2,358 |
728 |
3,086 |
||
|
Taxes on Earnings |
582 |
(126) |
456 |
||
|
Net Earnings |
1,776 |
854 |
2,630 |
||
|
Diluted Earnings per Share |
$ 1.01 |
$ 0.49 |
$ 1.50 |
||
Specified items reflect intangible amortization expense of
|
4Q24 |
|||||
|
As |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 465 |
$ (465) |
$ — |
||
|
Gross Margin |
5,567 |
673 |
6,240 |
||
|
R&D |
749 |
(59) |
690 |
||
|
SG&A |
2,907 |
(21) |
2,886 |
||
|
Other (income) expense, net |
(154) |
20 |
(134) |
||
|
Earnings before taxes |
2,030 |
733 |
2,763 |
||
|
Taxes on Earnings |
(7,199) |
7,613 |
414 |
||
|
Net Earnings |
9,229 |
(6,880) |
2,349 |
||
|
Diluted Earnings per Share |
$ 5.27 |
$ (3.93) |
$ 1.34 |
||
Specified items reflect intangible amortization expense of
|
Non-GAAP Reconciliation of Financial Information Twelve Months Ended (in millions, except per share data) (unaudited) |
|||||
|
12M25 |
|||||
|
As |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 1,682 |
$ (1,682) |
$ — |
||
|
Gross Margin |
23,327 |
1,824 |
25,151 |
||
|
R&D |
2,942 |
(112) |
2,830 |
||
|
SG&A |
12,332 |
(312) |
12,020 |
||
|
Other (income) expense, net |
(548) |
(48) |
(596) |
||
|
Earnings before taxes |
8,466 |
2,296 |
10,762 |
||
|
Taxes on Earnings |
1,942 |
(220) |
1,722 |
||
|
Net Earnings |
6,524 |
2,516 |
9,040 |
||
|
Diluted Earnings per Share |
$ 3.72 |
$ 1.43 |
$ 5.15 |
||
Specified items reflect intangible amortization expense of
|
12M24 |
|||||
|
As |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 1,878 |
$ (1,878) |
$ — |
||
|
Gross Margin |
21,366 |
2,213 |
23,579 |
||
|
R&D |
2,844 |
(140) |
2,704 |
||
|
SG&A |
11,697 |
(117) |
11,580 |
||
|
Other (income) expense, net |
(376) |
(163) |
(539) |
||
|
Earnings before taxes |
7,013 |
2,633 |
9,646 |
||
|
Taxes on Earnings |
(6,389) |
7,835 |
1,446 |
||
|
Net Earnings |
13,402 |
(5,202) |
8,200 |
||
|
Diluted Earnings per Share |
$ 7.64 |
$ (2.97) |
$ 4.67 |
||
Specified items reflect intangible amortization expense of
A reconciliation of the fourth-quarter tax rates for 2025 and 2024 is shown below:
|
4Q25 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 2,358 |
$ 582 |
24.7 % |
1) |
||
|
Specified items |
728 |
(126) |
||||
|
Excluding specified items |
$ 3,086 |
$ 456 |
14.8 % |
|||
|
4Q24 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 2,030 |
$ (7,199) |
(354.6 %) |
2) |
||
|
Specified items |
733 |
7,613 |
||||
|
Excluding specified items |
$ 2,763 |
$ 414 |
15.0 % |
|||
|
1) |
2025 Taxes on Earnings includes the recognition of approximately |
|
2) |
2024 Taxes on Earnings includes |
A reconciliation of the year-to-date tax rates for 2025 and 2024 is shown below:
|
12M25 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 8,466 |
$ 1,942 |
22.9 % |
3) |
||
|
Specified items |
2,296 |
(220) |
||||
|
Excluding specified items |
$ 10,762 |
$ 1,722 |
16.0 % |
|||
|
12M24 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 7,013 |
$ (6,389) |
(91.1 %) |
4) |
||
|
Specified items |
2,633 |
7,835 |
||||
|
Excluding specified items |
$ 9,646 |
$ 1,446 |
15.0 % |
|||
|
3) |
2025 Taxes on Earnings includes the recognition of approximately |
|
4) |
2024 Taxes on Earnings includes |
|
Non-GAAP Revenue Reconciliation Twelve Months Ended December 31, 2025 and 2024 ($ in millions) (unaudited) |
|||||||||||
|
12M25 |
12M24 |
% Change vs. 12M24 |
|||||||||
|
Non-GAAP |
|||||||||||
|
|
|
Impact |
Adjusted |
Reported |
Adjusted |
Organic |
|||||
|
|
44,328 |
41,950 |
(13) |
41,937 |
5.7 |
5.7 |
5.5 |
||||
|
|
17,126 |
16,323 |
(13) |
16,310 |
4.9 |
5.0 |
5.0 |
||||
|
Intl |
27,202 |
25,627 |
— |
25,627 |
6.1 |
6.1 |
5.9 |
||||
|
Total Nutrition |
8,451 |
8,413 |
(13) |
8,400 |
0.4 |
0.5 |
1.2 |
||||
|
|
3,606 |
3,689 |
(13) |
3,676 |
(2.3) |
(1.9) |
(1.9) |
||||
|
Intl |
4,845 |
4,724 |
— |
4,724 |
2.6 |
2.6 |
3.7 |
||||
|
Adult Nutrition |
4,477 |
4,390 |
(13) |
4,377 |
2.0 |
2.3 |
3.0 |
||||
|
|
1,448 |
1,481 |
(13) |
1,468 |
(2.2) |
(1.4) |
(1.4) |
||||
|
Intl |
3,029 |
2,909 |
— |
2,909 |
4.1 |
4.1 |
5.1 |
||||
|
(a) |
Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in |
|
Details of Specified Items Fourth Quarter Ended (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or |
Restructuring |
Intangible |
Other (c) |
Total |
|||||
|
Gross Margin |
$ 2 |
$ 3 |
$ 422 |
$ 1 |
$ 428 |
||||
|
R&D |
— |
(14) |
— |
(15) |
(29) |
||||
|
SG&A |
(38) |
(51) |
— |
(165) |
(254) |
||||
|
Other (income) expense, net |
(8) |
(3) |
— |
(6) |
(17) |
||||
|
Earnings before taxes |
$ 48 |
$ 71 |
$ 422 |
$ 187 |
728 |
||||
|
Taxes on Earnings (d) |
(126) |
||||||||
|
Net Earnings |
$ 854 |
||||||||
|
Diluted Earnings per Share |
$ 0.49 |
||||||||
|
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." |
|
|
a) |
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans. |
|
c) |
Other includes |
|
d) |
Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately |
|
Details of Specified Items Fourth Quarter Ended (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or |
Restructuring |
Intangible |
Other (c) |
Total |
|||||
|
Gross Margin |
$ — |
$ 49 |
$ 465 |
$ 159 |
$ 673 |
||||
|
R&D |
(1) |
(20) |
— |
(38) |
(59) |
||||
|
SG&A |
(5) |
(22) |
— |
6 |
(21) |
||||
|
Other (income) expense, net |
(2) |
— |
— |
22 |
20 |
||||
|
Earnings before taxes |
$ 8 |
$ 91 |
$ 465 |
$ 169 |
733 |
||||
|
Taxes on Earnings (d) |
7,613 |
||||||||
|
Net Earnings |
$ (6,880) |
||||||||
|
Diluted Earnings per Share |
$ (3.93) |
||||||||
|
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." |
|
|
a) |
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
|
c) |
Other includes incremental costs to comply with the |
|
d) |
Reflects the net tax benefit associated with the specified items, including non-cash valuation allowance adjustments. |
|
Details of Specified Items Twelve Months Ended December 31, 2025 (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or |
Restructuring |
Intangible |
Other (c) |
Total |
|||||
|
Gross Margin |
$ 3 |
$ 128 |
$ 1,682 |
$ 11 |
$ 1,824 |
||||
|
R&D |
(1) |
(56) |
— |
(55) |
(112) |
||||
|
SG&A |
(53) |
(100) |
— |
(159) |
(312) |
||||
|
Other (income) expense, net |
(26) |
(3) |
— |
(19) |
(48) |
||||
|
Earnings before taxes |
$ 83 |
$ 287 |
$ 1,682 |
$ 244 |
2,296 |
||||
|
Taxes on Earnings (d) |
(220) |
||||||||
|
Net Earnings |
$ 2,516 |
||||||||
|
Diluted Earnings per Share |
$ 1.43 |
||||||||
|
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." |
|
|
a) |
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans. |
|
c) |
Other includes |
|
d) |
Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately |
|
Details of Specified Items Twelve Months Ended December 31, 2024 (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or |
Restructuring |
Intangible |
Other (c) |
Total |
|||||
|
Gross Margin |
$ 2 |
$ 125 |
$ 1,878 |
$ 208 |
$ 2,213 |
||||
|
R&D |
(5) |
(21) |
— |
(114) |
(140) |
||||
|
SG&A |
(37) |
(39) |
— |
(41) |
(117) |
||||
|
Other (income) expense, net |
(155) |
— |
— |
(8) |
(163) |
||||
|
Earnings before taxes |
$ 199 |
$ 185 |
$ 1,878 |
$ 371 |
2,633 |
||||
|
Taxes on Earnings (d) |
7,835 |
||||||||
|
Net Earnings |
$ (5,202) |
||||||||
|
Diluted Earnings per Share |
$ (2.97) |
||||||||
|
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." |
|
|
a) |
Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
|
c) |
Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments. |
|
d) |
Reflects the net tax benefit associated with the specified items, including non-cash valuation allowance adjustments. |
View original content:https://www.prnewswire.com/news-releases/abbott-reports-fourth-quarter-and-full-year-2025-results-issues-2026-financial-outlook-302668032.html
SOURCE
Abbott Financial: Michael Comilla, 224-668-1872, Tamika McLoughlin, 224-399-5082, Randy Blakley, 224-668-0036, or Abbott Media: Karen Twigg May, 224-668-2681, Kate Dyer, 224-668-9965
